Market Overview

UPDATE: Deutsche Bank Initiates Buy on Achillion Pharmaceuticals

Related ACHN
Morning Market Losers
Benzinga's Top #PreMarket Losers
Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds (Investor's Business Daily)

Deutsche Bank initiated its coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Buy rating and a price target of $12 per share.

Deutsche Bank said, "ACHN's first R&D Day is 9/27. We believe ACHN has HCV drugs that will be very competitive in a big HCV market. … We think 3102 will show easily over 3 logs of viral reduction making it very competitive relative to all classes of HCV drugs. Our focus will be on the resistance profile for 3102. We think 3102 could work in mutations where first gen NS5As (ABT&GILD) do not. We expect some color on this at R&D Day."

Achillion Pharmaceuticals closed at $8.28 on Tuesday.

Latest Ratings for ACHN

May 2015William BlairUpgradesMarket PerformOutperform
May 2015UBSDowngradesBuyNeutral
May 2015JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Deutsche BankInitiation Pre-Market Outlook Analyst Ratings


Related Articles (ACHN)

Get Benzinga's Newsletters